Vincristine

Approved Uses

Vincristine is a chemotherapy medication used to treat several different types of cancer. It is frequently used in combination with other anticancer drugs to increase effectiveness.

Healthcare providers commonly prescribe vincristine for the following conditions:

• Acute lymphoblastic leukemia (ALL): A fast-growing cancer of the white blood cells.
• Hodgkin lymphoma and non-Hodgkin lymphoma: Cancers that originate in the immune system.
• Wilms tumor: A specific type of kidney cancer that occurs most often in children.
• Neuroblastoma: A cancer that develops in nerve tissue, typically affecting infants and young children.
• Rhabdomyosarcoma: A cancer that develops in the body's soft tissues, such as muscle.

Additional Applications

Vincristine may also be used to treat other malignancies, including certain types of brain tumors and other soft tissue cancers. A specific liposomal form of the medication is used for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia when the disease has returned or failed to respond to other treatments.

Mechanism of Action

Vincristine works by disrupting the internal structures that cancer cells need to reproduce. It is specifically designed to target cells during the process of division, which is a hallmark of cancer growth.

The medication functions through the following steps:

• Targeting Microtubules: To divide, a cell must create a scaffold called a mitotic spindle. This scaffold is made of proteins called microtubules.
• Blocking Assembly: Vincristine binds to these proteins and prevents them from forming the necessary scaffold.
• Halting Division: Without a functioning spindle, the cell cannot separate its genetic material to create a new cell. This stops the cell cycle in its tracks.

Because cancer cells divide more frequently than most healthy cells, they are more likely to be affected by this process. When a cell is unable to complete division, it typically stops growing and eventually dies.

Common Side Effects

Many people receiving vincristine experience side effects as the body adjusts to the medication. Common symptoms include:

• Hair loss (alopecia)
• Nausea and vomiting
• Constipation or stomach pain
• Loss of appetite and weight loss
• Mouth sores
• Headache

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact your healthcare provider right away if you experience:

• Numbness, tingling, or burning sensations in the hands or feet (peripheral neuropathy)
• Muscle weakness, clumsiness, or difficulty walking
• Jaw pain, joint pain, or bone pain
• Changes in vision or hearing
• Severe constipation, bloating, or an inability to have a bowel movement
• Difficulty urinating
• Signs of infection, such as fever, chills, or sore throat
• Unusual bleeding or bruising
• Shortness of breath or sudden wheezing

Vincristine can cause severe tissue damage if it leaks out of the vein during administration. Inform your medical team immediately if you feel any burning, pain, redness, or swelling at the injection site.

Fatal Administration Warning

Vincristine must only be given intravenously. Administration into the spinal fluid (intrathecal injection) is usually fatal. Syringes containing this medication should be clearly labeled to prevent administration errors.

Nerve and Muscle Toxicity

Nerve damage, known as peripheral neuropathy, is a common and often dose-limiting side effect. Symptoms may include:

• Numbness, tingling, or a burning sensation in the hands or feet.
• Muscle weakness or difficulty walking.
• Loss of deep tendon reflexes.
• Jaw pain or vocal cord weakness.

These symptoms may persist for a long time after treatment stops. People with pre-existing neuromuscular conditions, such as Charcot-Marie-Tooth syndrome, are at a higher risk for severe nerve damage.

Gastrointestinal Complications

Vincristine can cause severe constipation or a condition where the bowels stop moving (paralytic ileus). This is particularly common in pediatric patients. Healthcare providers may recommend a prophylactic bowel regimen to manage this risk.

Tissue Damage at Injection Site

If vincristine leaks out of the vein into the surrounding tissue (extravasation), it can cause severe local irritation, pain, and tissue death (necrosis). The injection site must be monitored closely during administration.

Other Precautions

• Breathing Problems: Acute shortness of breath and severe muscle spasms in the airways (bronchospasm) have been reported, especially when vincristine is used with mitomycin-C.
• Pregnancy: This medication can cause harm to an unborn baby. Effective contraception is necessary during treatment.
• Liver Function: Because the liver processes this drug, patients with liver disease may require dose adjustments to avoid increased toxicity.

Pregnancy

Vincristine can cause harm to an unborn baby if used during pregnancy. Research indicates that the medication may lead to birth defects or other developmental issues. It is important to inform a healthcare provider immediately if pregnancy occurs or is planned during treatment.

Healthcare providers typically recommend using effective birth control methods during treatment with vincristine. This often applies to both men and women to prevent pregnancy while the drug is being administered and for a period of time afterward.

Breastfeeding

It is currently unknown whether vincristine passes into human breast milk. However, because the medication has the potential to cause serious adverse reactions in nursing infants, breastfeeding is generally not recommended during treatment. Patients should consult with their healthcare team to discuss the risks and benefits of continuing or stopping breastfeeding while receiving this medication.

Dosage Forms

Vincristine is supplied as a liquid solution for injection. It is available in two primary formulations:

• Vincristine Sulfate Injection: A sterile liquid solution.
• Vincristine Sulfate Liposome Injection: A specialized formulation where the medication is contained within liposomes.

This medication is provided in vials and is intended for intravenous administration only. It must be administered by a healthcare professional in a clinical setting. Administration by any other route, particularly into the spinal fluid, is fatal.

FDA Approval and Indications

Vincristine sulfate was first approved by the U.S. Food and Drug Administration (FDA) in 1963. It is indicated for the treatment of several pediatric and adult malignancies, including:

• Acute leukemia
• Hodgkin's disease
• Non-Hodgkin's malignant lymphomas
• Rhabdomyosarcoma
• Neuroblastoma
• Wilms' tumor

A liposomal formulation of vincristine is also FDA-approved for the treatment of adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) whose disease has progressed after two or more anti-leukemia therapies.

Boxed Warning

Vincristine carries a boxed warning regarding its route of administration. It is for intravenous use only. Administration by any other route, particularly intrathecal (into the spinal fluid), is fatal. To prevent administration errors, the FDA requires specific labeling and packaging precautions, such as labeling syringes with warnings that the drug is fatal if given by other routes.

Regulatory Safety Communications

Due to the high risk of fatal medication errors associated with accidental intrathecal injection, regulatory bodies and health organizations have issued multiple safety communications. These guidelines emphasize that vincristine should be diluted in a small-volume intravenous bag rather than a syringe to minimize the risk of accidental spinal administration. If the medication is accidentally administered intrathecally, immediate neurosurgical intervention is required, though the prognosis in such cases is generally very poor.

FDA-Approved Uses

Vincristine sulfate is approved by the U.S. Food and Drug Administration (FDA) for use in both pediatric and adult patients to treat several types of cancer. These indications include:

• Acute leukemia
• Hodgkin's disease
• Non-Hodgkin's lymphomas
• Rhabdomyosarcoma
• Neuroblastoma
• Wilms' tumor

A liposomal formulation of vincristine is also FDA-approved specifically for adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) whose disease has returned or progressed after two or more previous treatments.

Boxed Warnings

The FDA has issued a boxed warning for vincristine regarding its administration. It is for intravenous use only. Fatalities have occurred when the medication was accidentally administered into the spinal fluid (intrathecal injection).

Vincristine is also classified as a vesicant. The FDA warns that if the drug leaks into the surrounding tissue during administration (extravasation), it can cause severe local irritation, pain, and tissue damage.

Regulatory Status

Vincristine was first approved by the FDA in the 1960s. It is available as a generic medication, though the liposomal formulation may be available only under specific brand names. Because of its high toxicity and the risk of fatal errors, the FDA requires strict labeling and administration protocols, including labeling syringes with warnings that the drug is for intravenous use only.